Company intelligence / Profile preview
Aminex Therapeutics
- Ownership
- Private
- Employees
- ~5
- Development stage
- Other
Overview
Aminex Therapeutics has advanced its lead combination therapy—AMXT 1501 plus DFMO—into Phase 1/2 clinical trials. The approach aims to deplete polyamines in the tumor microenvironment to enhance immune response against cancer. Early animal studies have shown promising efficacy in inhibiting tumor growth and metastasis by overcoming immunosuppression mediated by polyamines and MDSCs. Clinical trials are ongoing or planned for various solid tumors including neuroblastoma, CNS tumors, sarcomas, HNSCC, mesothelioma, and gliomas. Some early-stage trials have been terminated or withdrawn but new investigator-led studies are planned.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules (notably polyamine uptake inhibitors and anti-metabolites)
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Aminex Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aminex Therapeutics.